⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PHVS News
Pharvaris N.V. Ordinary Shares
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
globenewswire.com
PHVS
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
globenewswire.com
PHVS
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
globenewswire.com
PHVS
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
globenewswire.com
PHVS
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
globenewswire.com
PHVS
Pharvaris Outlines 2026 Strategic Priorities
globenewswire.com
PHVS
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
globenewswire.com
PHVS
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
PHVS
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
globenewswire.com
PHVS